
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT
- About


Predictive Oncology Inc (POAI)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: POAI (1-star) is currently NOT-A-BUY. Pass it for now.
1 Year Target Price $3
1 Year Target Price $3
0 | Strong Buy |
0 | Buy |
1 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 8.02% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 8.89M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) 1 | Beta 1.19 | 52 Weeks Range 0.55 - 2.25 | Updated Date 08/15/2025 |
52 Weeks Range 0.55 - 2.25 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2073.29% |
Management Effectiveness
Return on Assets (TTM) -73.2% | Return on Equity (TTM) -490.37% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10499739 | Price to Sales(TTM) 5.14 |
Enterprise Value 10499739 | Price to Sales(TTM) 5.14 | ||
Enterprise Value to Revenue 6.31 | Enterprise Value to EBITDA -0.51 | Shares Outstanding 10222200 | Shares Floating 8826496 |
Shares Outstanding 10222200 | Shares Floating 8826496 | ||
Percent Insiders 1.11 | Percent Institutions 1.96 |
Upturn AI SWOT
Predictive Oncology Inc

Company Overview
History and Background
Predictive Oncology Inc. (formerly known as Cancer Research Technologies, Inc.) was founded with the aim of developing advanced technologies to improve cancer treatment outcomes. The company has evolved through strategic acquisitions and a focus on predictive models and personalized medicine.
Core Business Areas
- Drug Discovery & Development Services: Offers drug discovery and development services using its AI-powered platform, PeptiDream, and other technologies, with a focus on identifying and validating drug candidates for various cancers.
- TumorGenesis: Offers a 3D tumor microenvironment platform that simulates the conditions within a tumor, enabling more accurate drug testing and prediction of patient responses. This includes testing and development services for pharmaceutical companies.
- Skyline Medical: Focuses on the STREAMWAY System, a fully automated, direct-to-drain medical fluid disposal system.
Leadership and Structure
The leadership team includes executives with experience in biotechnology, pharmaceuticals, and finance. The organizational structure is composed of research and development, commercial operations, and administrative functions.
Top Products and Market Share
Key Offerings
- PeptiDream Platform: AI-powered platform used for drug discovery and development. Competitors include Schru00f6dinger and Exscientia. Difficult to determine specific market share but is a growing market.
- TumorGenesis 3D Microenvironment: A 3D tumor microenvironment platform for drug testing. Competitors include Insphero and MIMETAS. Similar to PeptiDream Market share is difficult to determine.
- STREAMWAY System: Fully automated medical fluid disposal system. Competitors include Stryker and Cardinal Health. Revenue from this product provides a stable revenue base, but market share is relatively small compared to larger players in medical device market.
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for personalized medicine and advanced drug discovery platforms. Oncology is a major focus area, with significant investments in research and development.
Positioning
Predictive Oncology Inc. positions itself as a leader in AI-powered drug discovery and development services, with a focus on improving cancer treatment outcomes through personalized medicine.
Total Addressable Market (TAM)
The global oncology market is projected to reach hundreds of billions of dollars. Predictive Oncology Inc. is positioned to capture a share of this market through its drug discovery and development services, and predictive technologies.
Upturn SWOT Analysis
Strengths
- AI-powered drug discovery platform
- 3D tumor microenvironment platform
- Established customer base
- STREAMWAY System provides recurring revenue
Weaknesses
- Limited financial resources
- Reliance on partnerships for drug development
- History of operating losses
- Stock price volatility
Opportunities
- Increasing demand for personalized medicine
- Partnerships with pharmaceutical companies
- Expansion into new markets
- Advancements in AI and machine learning
Threats
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- CRIS
- VIRI
- CLVS
Competitive Landscape
Predictive Oncology Inc. faces competition from larger pharmaceutical companies and biotechnology firms. The company's AI-powered platform and 3D tumor microenvironment platform provide a competitive advantage, but limited financial resources pose a challenge.
Major Acquisitions
Skyline Medical
- Year: 2019
- Acquisition Price (USD millions): 11.2
- Strategic Rationale: Acquisition of Skyline Medical added a stable revenue base from the STREAMWAY System, diversifying the company's revenue streams.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of rapid expansion followed by periods of contraction.
Future Projections: Future growth projections depend on successful partnerships and commercialization of its drug discovery and development services. Analyst estimates vary widely.
Recent Initiatives: Recent strategic initiatives include expansion of its AI-powered platform, and collaboration agreements with pharmaceutical companies.
Summary
Predictive Oncology Inc. is attempting to leverage its AI and 3D tumor modelling to enhance cancer treatment and discovery. While they have some innovative technologies, they have challenges in reaching the profitability and have history of operating losses. They need to improve the bottom line and make improvements to keep the company solvent. The company's dependence on partnerships could make it vulnerable to changes in the biotech climate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (10-K, 10-Q), Press Releases, Analyst Reports, Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share percentages are estimates based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Predictive Oncology Inc
Exchange NASDAQ | Headquaters Pittsburgh, PA, United States | ||
IPO Launch date 2018-01-29 | CEO & Chairman Mr. Raymond F. Vennare | ||
Sector Healthcare | Industry Health Information Services | Full time employees 23 | Website https://predictive-oncology.com |
Full time employees 23 | Website https://predictive-oncology.com |
Predictive Oncology Inc., a knowledge and science-driven company, applies artificial intelligence (AI) to support the discovery and development of cancer therapies. It operates through two segments, Pittsburgh and Eagan. The Pittsburgh segment provides services that include the application of AI using its proprietary biobank of 150,000+ tumor samples. This segment also creates proprietary 3D culture models used in drug development. Its Eagan segment produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is headquartered in Pittsburgh, Pennsylvania.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.